(Q28071569)

Amandine Manon

2

1 reference

Christophe Chassaing

3

1 reference

Andy Lewis

4

1 reference

Laurent Bertocchi

5

1 reference

Joel Richard

6

1 reference

Alexandria T. Phan

7

1 reference

language of work or name

1 reference

December 2016

1 reference

Journal of gastrointestinal cancer

1 December 2016

8 references

19 March 2019

24 March 2019

3 April 2019

13 November 2019

17 November 2019

20 November 2019

19 December 2019

14 September 2020

9 references

19 March 2019

24 March 2019

3 April 2019

13 November 2019

17 November 2019

20 November 2019

19 December 2019

14 September 2020

47

1 reference

issue

4

1 reference

page(s)

366-374

1 reference

Creative Commons Attribution 4.0 International

copyright license

8 references

19 March 2019

24 March 2019

3 April 2019

13 November 2019

17 November 2019

20 November 2019

19 December 2019

on focus list of Wikimedia project

14 September 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

The structural basis of protein folding and its links with human disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Amyloid as a depot for the formulation of long-acting drugs

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

An update on gastroenteropancreatic neuroendocrine tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Cancer treatment using peptides: current therapies and future prospects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

The expanding role of somatostatin analogs in the management of neuroendocrine tumors.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Formulation strategies for sustained release of proteins

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

The management of neuroendocrine tumours: current and future medical therapy options

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Control of peptide nanotube diameter by chemical modifications of an aromatic residue involved in a single close contact

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

The epidemiology of gastroenteropancreatic neuroendocrine tumors.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Molecular origin of the self-assembly of lanreotide into nanotubes: a mutational approach

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Self-association process of a peptide in solution: from beta-sheet filaments to large embedded nanotubes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Biomimetic organization: Octapeptide self-assembly into nanotubes of viral capsid-like dimension

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Elucidation of the self-assembly pathway of lanreotide octapeptide into beta-sheet nanotubes: role of two stable intermediates

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5138269

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

First report on the efficacy of l-alanine-based in situ-forming implants for the long-term parenteral delivery of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Effect of the size of biodegradable microparticles on drug release: experiment and theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Experimental observation of double-walled peptide nanotubes and monodispersity modeling of the number of walls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Self-assembly of the octapeptide lanreotide and lanreotide-based derivatives: the role of the aromatic residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Hierarchical architectures by synergy between dynamical template self-assembly and biomineralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Improving the success rate of gluteal intramuscular injections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Are IM injections IM in obese and overweight females? A study in injection technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12029-016-9866-9

Structural Role of Counterions Adsorbed on Self-Assembled Peptide Nanotubes

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/27619395

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

1 reference

https://pubmed.ncbi.nlm.nih.gov/27619395

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems

1 reference

https://pubmed.ncbi.nlm.nih.gov/27619395